RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Results of Operations and Financial Condition

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02.

Results of Operation and Financial Condition

On May 9, 2017, Ritter Pharmaceuticals, Inc. (the Company),
issued a press release announcing the financial results for the
three-month period ending March 31, 2017, entitled Ritter
Pharmaceuticals Reports First Quarter 2017 Financial Results and
Provides Business Updates (the Press Release). A copy of the
Press Release is furnished as Exhibit 99.1 hereto and is
incorporated herein by reference.

The information contained in this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section 18 of the United State Securities Exchange
Act of 1934, as amended, or otherwise subject to the liability of
Section 18. Furthermore, the information shall not be deemed
incorporated by reference into any registration statement or any
other filing under the United States Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
references in such filings.

Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated May 9, 2017, entitled Ritter
Pharmaceuticals Reports First Quarter 2017 Financial Results
and Provides Business Updates


About RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health. The Company’s compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) Recent Trading Information

RITTER PHARMACEUTICALS, INC. (NASDAQ:RTTR) closed its last trading session down -0.016 at 0.644 with 823,349 shares trading hands.

An ad to help with our costs